Pharmacy Medical News about Glioblastoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma
Expert Opinion on Investigational Drugs, 09/21/09

Dietrich J et al. – Cediranib is an effective drug in patients with glioblastoma, acting through inhibition of angiogenesis and normalization of tumor vasculature. Reduction of vasogenic brain edema is a key component of its treatment effect in this patient population. The primary side effects of cediranib include fatigue, diarrhea and hypertension.

<< Previous
Current data of targeted therapies for the treatment of...

Next >>
Pregabalin: In the Treatment of Postherpetic Neuralgia

Distribution, cellular localization, and therapeutic potential of the tumor-associated antigen Ku70/80 in glioblastoma multiforme
Journal of Neuro-Oncology, 10/28/09 Relevance Score: 88%%

Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment
Clinical Cancer Research, 10/01/09 Relevance Score: 88%%

Multiple extracranial metastases from secondary glioblastoma multiforme: a case report and review of the literature
Journal of Neuro-Oncology, 11/18/09 Relevance Score: 87%%

Antiglioma Immunological Memory in Response to Conditional Cytotoxic/Immune-Stimulatory Gene Therapy: Humoral and Cellular Immunity Lead to Tumor Regression
Clinical Cancer Research, 10/06/09 Relevance Score: 87%%

Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme
Journal of Neuro-Oncology, 10/01/09 Relevance Score: 87%%